Immunovia Management

Management Kriterienprüfungen 1/4

Immunovia's CEO ist Jeff Borcherding , ernannt in Apr 2023, hat eine Amtszeit von 1.17 Jahren. besitzt direkt 0.77% der Aktien des Unternehmens, im Wert von €46.29K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.3 Jahre bzw. 4.1 Jahre.

Wichtige Informationen

Jeff Borcherding

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	1.2yrs
Eigentum des Geschäftsführers	0.8%
Durchschnittliche Amtszeit des Managements	1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Jeff Borcherding (51 yo)

1.2yrs

Amtszeit

Mr. Jeff Borcherding served as Chief Executive Officer of US, Immunovia, Inc. at Immunovia AB (publ) since 2022 until April 2023. He serves as Global Chief Executive Officer of Immunovia AB (publ) since Ap...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jeff Borcherding	Global Chief Executive Officer & President	1.2yrs	keine Daten	0.77% SEK 49.4k
Karin Liwendahl	Chief Financial Officer	2.2yrs	keine Daten	keine Daten
Karl Stone	Chief Operating Officer	1.3yrs	keine Daten	keine Daten
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.3yrs	keine Daten	keine Daten

1.3yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: 1YRDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Peter Hongaard Andersen	Independent Chairman	4.1yrs	SEK 475.00k	keine Daten
Hans Johansson	Independent Director	8.4yrs	SEK 280.00k	0.10% SEK 6.5k
Margaret Tempero	Member of Medical Advisory Board	8yrs	keine Daten	keine Daten
Diane Simeone	Member of Medical Advisory Board	7.9yrs	keine Daten	keine Daten
Michael Lofman	Independent Director	1.1yrs	SEK 175.00k	keine Daten
Valerie Bogdan-Powers	Independent Director	less than a year	SEK 16.00k	keine Daten
Stephen Pereira	Member of Medical Advisory Board	6.9yrs	keine Daten	keine Daten
Melissa Farina	Independent Director	less than a year	SEK 16.00k	keine Daten
Martin Moller	Independent Director	3.1yrs	SEK 302.00k	keine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: 1YRDie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).

Immunovia Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Immunovia AB (publ) Announces Board Changes

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Recent updates

Immunovia AB (publ) to Report Fiscal Year 2024 Results on Feb 25, 2025

Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina

Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test

Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study

Full year 2023 earnings released: kr7.95 loss per share (vs kr7.43 loss in FY 2022)

Immunovia AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Immunovia AB (Publ) Elects Melissa Farina and Valerie Bogdan-Powers as New Board Members

Third quarter 2023 earnings released: kr0.91 loss per share (vs kr1.01 loss in 3Q 2022)

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Revenue and earnings growth

Immunovia AB (publ) Announces Board Changes

First quarter 2023 earnings released: kr2.28 loss per share (vs kr1.95 loss in 1Q 2022)

Immunovia AB (Publ) Announces Board Changes

Philipp Von Hugo Resigns from Immunovia's Board at His Own Request

Full year 2022 earnings released: kr7.43 loss per share (vs kr6.89 loss in FY 2021)

Forecast to breakeven in 2024

Immunovia Realigning Swedish Operations with Strategic Priorities and its Focus on the US Commercialization of the Immray Pancan-D Test

Immunovia AB (Publ) Appoints Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs, Effective February 1, 2023

Immunovia Inc. Appoints Jon Hager as New National Sales Director

Forecast to breakeven in 2024

Immunovia AB (publ), Annual General Meeting, Apr 27, 2023

Immunovia AB (Publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Immunovia AB Announces Executive Management Team Appointments

Immunovia AB Announces Positive Update on Physician Experience Program with IMMrayTM PanCan-d

Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test

Second quarter 2022 earnings released: kr1.49 loss per share (vs kr2.18 loss in 2Q 2021)

Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test

Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly Onset Type Diabetics Moves into Next Phase

Immunovia AB Announces Results from PanFAM-1 Study

Immunovia AB (publ) Announces Executive Changes

Immunovia Names Philipp Mathieu as Chief Executive Officer

Immunovia AB Appoints Natalie Carfora as Head of Market Access US Subsidiary

First quarter 2022 earnings released: kr1.95 loss per share (vs kr1.04 loss in 1Q 2021)

Immunovia AB (Publ) Announces Board Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: kr1.60 loss per share (vs kr1.68 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.18 loss per share (vs kr1.67 loss in 2Q 2020)

Immunovia AB (publ) Receives Approval to Begin Testing Patients for Pancreatic Cancer with the Immrayt Pancan-D Test

Chief Executive Officer recently bought €67k worth of stock

Independent Director recently bought €29k worth of stock

First quarter 2021 earnings released: kr1.04 loss per share (vs kr1.41 loss in 1Q 2020)

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter